More recent studies have shown that CML patients who respond to interferon [56] or other immune modulatory therapies such as heat shock protein vaccination generally have higher CD56+, CD16+ NK cell mediated cytotoxic activity towards K562 cells as compared to treatment non-responders [57]. Here, NCAM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.